The price of TG Therapeutics Inc. (NASDAQ:TGTX) shares last traded on Wall Street fell -3.36% to $27.03.
Based on available information, 9 analysts follow TG Therapeutics Inc. (NASDAQ:TGTX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $42.00 and a low of $6.00, we find $35.00. Given the previous closing price of $27.97, this indicates a potential upside of 25.13 percent. TGTX stock price is now 17.52% away from the 50-day moving average and 106.32% away from the 200-day moving average. The market capitalization of the company currently stands at $4.13B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Among analysts, 0 rate the stock a hold while 7 rate it a buy. Brokers who have rated the stock have averaged $30.50 as their price target over the next twelve months.
In other news, Echelard Yann, Director bought 9,000 shares of the company’s stock on Jan 06. The stock was bought for $95,760 at an average price of $10.64. Upon completion of the transaction, the Director now directly owns 201,848 shares in the company, valued at $5.46 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 04, Director Charney Laurence N sold 30,000 shares of the business’s stock. A total of $333,000 was realized by selling the stock at an average price of $11.10. This leaves the insider owning 234,729 shares of the company worth $6.34 million. Insiders disposed of 30,000 shares of company stock worth roughly $0.81 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TGTX stock. A new stake in TG Therapeutics Inc. shares was purchased by DARWIN GLOBAL MANAGEMENT, LTD. during the first quarter worth $282,497,000. GHOST TREE CAPITAL, LLC invested $29,733,000 in shares of TGTX during the first quarter. In the first quarter, DRIEHAUS CAPITAL MANAGEMENT LLC acquired a new stake in TG Therapeutics Inc. valued at approximately $22,915,000. HOOD RIVER CAPITAL MANAGEMENT LLC acquired a new stake in TGTX for approximately $19,978,000. ARTAL GROUP S.A. purchased a new stake in TGTX valued at around $13,823,000 in the second quarter. In total, there are 273 active investors with 69.70% ownership of the company’s stock.
A candlestick chart of TG Therapeutics Inc. (NASDAQ: TGTX) showed a price of $28.00 on Thursday morning. During the past 12 months, TG Therapeutics Inc. has had a low of $3.48 and a high of $35.67. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.90, and a quick ratio of 2.50. The fifty day moving average price for TGTX is $23.25 and a two-hundred day moving average price translates $13.20 for the stock.
The latest earnings results from TG Therapeutics Inc. (NASDAQ: TGTX) was released for Mar, 2023. The company reported revenue of $7.8 million for the quarter, compared to $2.02 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 287.05 percent.
TG Therapeutics Inc.(TGTX) Company Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
